(Adnkronos) - “Lo studio Podcast ha evidenziato che più della metà dei pazienti è in un controllo non ottimale di malattia. C’è quindi bisogno di un ulteriore sforzo terapeutico per questi pazienti. Un altro dato importante è il disallineamento della percezione di gravità della malattia tra pazienti e medici. Questo gap clinico deve essere colmato anche attraverso la comunicazione”. A dirlo è Annalisa Iezzi, direttore medico di AbbVie, in occasione della conferenza stampa di presentazione dello studio osservazionale Podcast e dell'indagine sui pazienti Acquire_Ibd, intitolata ‘Malattia di Crohn e colite ulcerosa: diamo luce all’invisibile’, a cura di Abbvie.
Category
🗞
NewsTranscript
00:00 [Music]
00:04 Today we present the first data of the Podcast studio, which is an observational study
00:08 that AVI has conducted worldwide, but today we are talking about the Italian clinical champion.
00:14 So, more than 200 patients, divided in half between patients with Crohn's disease and ulcerative colitis,
00:20 with questions about quality of life.
00:22 And these questions were going to evaluate the quality of life according to important clinical parameters,
00:28 validated according to an international consensus of scientific relevance, the STRIDE,
00:34 and then correlated with the patient's perception and the doctors who treat them.
00:39 Here is the first data, which I would like to highlight, that more than half of the patients, unfortunately,
00:44 are in an inoperative disease control.
00:47 There is therefore a need for further therapeutic effort for these patients.
00:52 Another relevant data is that of the misalignment of the perception of the severity of the disease,
00:58 and therefore of well-being, between patients and doctors.
01:01 There is therefore a need to fill this clinical gap, also by improving communication between doctor and patient.
01:07 And this element of communication is fundamental, especially in an area where we often talk about
01:13 invisible disease and disability.
01:15 Not because they are not visible, but because patients tend to suffer the stigma of a disease
01:21 that is not easy to talk about.
01:22 And we are here today for this reason as well.
01:24 AbbVie feels an ethical duty to talk about these diseases,
01:27 because we have been dealing with immunology for decades,
01:30 and in particular with rheumatology, gastroenterology and dermatology.
01:35 Each patient has a different experience of the disease,
01:41 depending on the clinical manifestations that express the severity of the disease
01:46 and the perception that the patient himself has.
01:48 Italy has an extremely relevant scientific community, also internationally,
01:53 so it is an honor to be able to bring clinical studies to Italy and bring new therapeutic solutions.
02:00 I was saying, currently we have more than 400 clinical studies with new experiments,
02:05 ranging from clinical trials with new therapeutic interventions.
02:09 We have more than two assets in association and alone in the area of gastroenterology,
02:14 up to observational studies that evaluate how therapeutic solutions fall into the Italian health reality.